Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Blocking Gene Expression Improves Outcomes in Blood Disease in Models
Disease Discoveries

Blocking Gene Expression Improves Outcomes in Blood Disease in Models

By Will DossNov 30, 2017
Share
Facebook Twitter Email
Peng Ji, MD, PhD, Department of Pathology, FSM.
Peng Ji, MD, PhD, associate professor of Pathology, was senior author on a study published in the Journal of Clinical Investigation.

Scientists successfully reduced the symptoms of a blood disease called myeloproliferative neoplasm in mouse models by interrupting an important regulatory pathway, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

Myeloproliferative neoplasm (MPN) is a bone marrow disease characterized by overproduction of blood cells. While it sometimes leads to cancer, blood clots are a major cause of mortality and morbidity in the disease, according to senior author Peng Ji, MD, PhD, associate professor of Pathology. Baobing Zhao, PhD, a postdoctoral fellow in Ji’s lab, was the lead author.

Many MPN patients with clots in a blood vessel — thrombosis — have a mutation in a protein-encoding gene called JAK2. One popular treatment inhibits the function of that mutated gene, but high doses of those drugs can cause anemia or low platelet count, as JAK2 is essential for blood cell production. Consequently, Northwestern Medicine scientists have been exploring other therapeutic pathways, Ji said.

One such pathway involves another gene, Pleckstrin-2, previously shown to be involved in red blood cell production. Ji and his colleagues discovered the gene was upregulated in MPN patients with the JAK2 mutation, presenting a therapeutic target.

Substantial clotting in lung tissue, shown by the large pink masses in the top image, was reduced with the loss of Plekstrin-2, shown in the bottom image.

“We wanted to use a genetic model to find out if Pleckstrin-2 had an impact on disease development,” said Ji, who is also a member of the Robert H. Lurie comprehensive Cancer Center of Northwestern University.

He and his collaborators created a mouse model with the Jak2 mutation and then turned off Pleckstrin-2. They found it drastically reduced blood clots and extended survival in the model.

“The risk of thrombosis was not completely cured because there are other factors aside from pleckstrin2, but we saw a very dramatic amelioration in blood clotting,” Ji said. “No factor of Jak2 has shown this rescue of lethality before.”

Next, Ji hopes to turn this discovery into an actionable therapy. He has begun generating a drug-based inhibitor for Pleckstrin 2 in hopes that it would have milder side effects when compared to the Jak2 inhibitor drug.

“We are looking for a molecule that can bind with Pleckstrin2 and block its functions. We’ve already screened compounds, and we have about 40 we are testing right now,” Ji said. “Mice with pleckstrin2 deactivated experienced fewer side effects compared to mice without Jak2, so we believe the Pleckstrin-2 inhibitor will generate fewer side effects as well.”

This work was supported by National Institute of Diabetes and Digestive and Kidney Disease grant DK102718, Department of Defense grant CA140119 and a Dixon Translational Research Grant. This work was also supported by National Heart, Lung, and Blood Institute grants HL112792, HL120846 and HL40387.

Cancer Genetics Pathology Research
Share. Facebook Twitter Email

Related Posts

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

Comments are closed.

Latest News

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.